GLP-1: The Midlife Plot Twist?
by: Valerie |
The tabloids do love running sensationalist stories about how so-and-so lost ‘X-amount of stones’, and now looks great (or dreadful).
This circus of body-shaming and categorising women according to their appearance in the mainstream media is nothing new, but with the rise of GLP-1 drugs, some may say that it’s now hitting new heights.
For perimenopausal and menopausal women, it’s often a tricky time for weight management.
Hormonal changes can influence appetite, fat distribution and how the body processes insulin.
As a result, women in this transition period are often marketed ‘wonder drugs’ like GLP-1 receptor agonists, or prescribed them by their GP.
Hormonal changes can influence hunger signals, potentially leading to increased appetite and cravings (1).
Oestrogen has a say in where your body stores fat. When levels drop, it can trigger a relocation from hips and thighs to centre stage: the belly (2).
When oestrogen dips, your body can get a bit rubbish at handling insulin (3). That means blood sugar swings get wilder, and weight gain can sneak in even when you're doing all the right things.
GLP-1 drugs, also known as GLP-1 receptor agonists, are a class of medications that mimic the naturally occurring hormone GLP-1 (4).
In simple terms, they mimic a hormone called GLP-1 (glucagon-like peptide-1), which is released in your gut after eating. This hormone does a few different things:
These drug effects have sparked interest in the medical world for women in perimenopause (and postmenopause) (8). Peri is a time when falling oestrogen can make blood sugar harder to manage, increase cravings, alter how the body stores fat and change cholesterol levels.
Of course, this is only part of the bigger picture. So stick with us as we explore the upsides, the limitations, risks and unanswered questions around GLP-1s.
GLP-1 meds might be known for weight loss, but there’s more here than meets the eye.
Some research suggests benefits for heart health, blood pressure, and cholesterol (9). However, while that’s worth noting, especially as oestrogen dips and risks to heart and metabolic health rise in midlife, long-term health (10) is rarely discussed.
And, yes, gleefully zipping up old dresses is one thing, but the full picture isn’t clear. There’s a bigger conversation taking place. And this time, it includes women like us.
That makes GLP-1s a pretty tricky territory.
Yep, curiosity is good, but it pays to stay cautious, too.
Another big issue is that GLP-1s don’t just reduce fat, they can chip away at muscle (11), too.
And let’s face it, muscle is already difficult to hold onto (12) once perimenopause kicks in. Without protein, strength training or movement, that loss can creep up on you.
Plus, muscle matters for more than just the classic Jennifer Aniston aesthetic value. It supports metabolism, balance, and blood sugar control (13), all super important when it comes to midlife. Basically, muscle mass is your secret weapon, not something to lose. Read more by wonderful fitness expert Liz Marsland.
Here’s what we do know. Most studies focus on diabetes or obesity (14).
So, if you're in the perimenopausal stage, but in good health, the research isn’t likely to be talking to you.
Moreover, some argue that there remains a lack of data on side effects (15) or outcomes (16) for women, especially in this stage of life. Also, there are claims GLP-1 agonists may interfere with hormonal medication, such as HRT (17).
GLP-1s mimic a gut hormone that helps control appetite and blood sugar.
Some may say they are relevant to perimenopause, as this stage affects fat storage, cravings and insulin. This may explain the growing interest in GLP-1, despite the research currently pointing in different directions.
There are some potential benefits being put forward beyond the obvious weight loss, like improved heart health and reduced inflammation.
But then muscle loss is a risk, and some experts warn that the long-term effects aren’t fully known.
So, GLP-1s. Interesting? Yes. A peri cure-all? Well, that remains to be seen.
For many of us, perimenopause can hit hard, littered with unexpected blood sugar crashes that leave you snapping at your colleague one minute and inhaling a stale flapjack the next.
So, here are the real deals to look for in a supplement when it comes to keeping things a bit more on track:
Quick Hint: They're all in Valerie Daily Essential
In research, it’s been shown to support blood sugar control and insulin sensitivity, especially in those with type 2 diabetes (18) or carrying extra weight (19).
Chromium is a pretty big name in the world of blood sugar-controlling nutrients. It helps cells respond better to insulin and can reduce sugar crashes and cravings. For women dealing with hormonal shifts, that can help take the edge off those mid-afternoon snack spirals.
This unsung hero helps your body respond better to insulin (20), which basically means it can help keep those sugar dips and cravings in check.
Magnesium is also good for sleep, stress (21) and not launching your laptop out the window. And it works both ways, in that improved sleep and better stress management are good news for your blood sugar. Win win…
Supports glucose metabolism (22), especially handy when your hormones get busy doing the Macarena and taking your energy levels with them. Additionally, this B vit is great for keeping those hangry outbursts to a minimum.
Low D3 is actually very common in perimenopause, (23) and something to look out for as it could be making blood sugar highs and lows even worse (24).
Why? This one very handy nutrient supports insulin sensitivity, mood and motivation, so you’re less likely to wish it was lunchtime at only 10 am.
Essential for how your body uses insulin and controls appetite (25). A bit of a blessing for blood sugar balance, especially when PMS, perimenopause and that Wednesday slump all gang up on you.
Valerie Daily Essential is here to steady the wobbles, helping you feel more focused, more balanced, and more like yourself. Because keeping your sh*t together shouldn’t hinge on a mid-afternoon sugar crash.
Chopra S, Sharma KA, Ranjan P, Malhotra A, Vikram NK, Kumari A. Weight management module for perimenopausal women: a practical guide for gynecologists. J Midlife Health. 2019;10(4):165-172. doi:10.4103/jmh.JMH_155_19 https://pmc.ncbi.nlm.nih.gov/articles/PMC6947726/
Chopra S, Sharma KA, Ranjan P, Malhotra A, Vikram NK, Kumari A. Weight management module for perimenopausal women: a practical guide for gynecologists. J Midlife Health. 2019;10(4):165-172. doi:10.4103/jmh.JMH_155_19https://pmc.ncbi.nlm.nih.gov/articles/PMC6947726/
Diabetes UK. Menopause and diabetes. Accessed May 14, 2025.https://www.diabetes.org.uk/living-with-diabetes/life-with-diabetes/menopause
Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025 Jan–. Updated February 29, 2024. Accessed May 14, 2025. https://www.ncbi.nlm.nih.gov/books/NBK551568/
Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15-27. doi:10.1111/j.1463-1326.2012.01663.x https://pmc.ncbi.nlm.nih.gov/articles/PMC3556522
Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15-27. doi:10.1111/j.1463-1326.2012.01663.xhttps://pmc.ncbi.nlm.nih.gov/articles/PMC3556522
Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181-187. doi:10.1007/s11154-014-9289-5 https://link.springer.com/article/10.1007/s11154-014-9289-5
Mikdachi H, Dunsmoor-Su R. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. Curr Opin Obstet Gynecol. 2025;37(2):97-101. doi:10.1097/GCO.0000000000001015. PMID: 39970049.https://pubmed.ncbi.nlm.nih.gov/39970049/
Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025 Jan–. Updated February 29, 2024. Accessed May 14, 2025. https://www.ncbi.nlm.nih.gov/books/NBK551568/
Alexander JT, Staab EM, Wan W, et al. The longer-term benefits and harms of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis. J Gen Intern Med. 2022;37(2):415-438. doi:10.1007/s11606-021-07105-9https://pubmed.ncbi.nlm.nih.gov/34508290/
Prado CM, et al. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785-787.https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00272-9/abstract
Sipilä S, Poutamo J. Muscle performance, sex hormones and training in peri-menopausal and post-menopausal women. Scand J Med Sci Sports. 2003;13(1):19-25. doi:10.1034/j.1600-0838.2003.20210.xhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1600-0838.2003.20210.x?sid=nlm%3Apubmed
Merz KE, Thurmond DC. Role of skeletal muscle in insulin resistance and glucose uptake. Compr Physiol. 2020;10(3):785-809. doi:10.1002/cphy.c190029 https://pmc.ncbi.nlm.nih.gov/articles/PMC8074531/
Liu Y, et al. The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr. 2023;118(3):614-626.https://ajcn.nutrition.org/article/S0002-9165(23)46846-3/fulltext
Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse. Drug Safety Update. Published October 24, 2024. Accessed May 14, 2025.https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse
National Institute for Health and Care Excellence (NICE). NICE recommended weight-loss drug to be made available in specialist NHS services. Published March 8, 2023. Accessed May 14, 2025. https://www.nice.org.uk/news/articles/nice-recommended-weight-loss-drug-to-be-made-available-in-specialist-nhs-services
Gray S, Hazell T, Price L, Thomas L. Injectable weight loss drugs, contraception and HRT – summary with practical action plan. Primary Care Women’s Health Society (PCWHS); 2024. Accessed May 14, 2025.https://www.pcwhs.co.uk/resources/116/injectable_weight_loss_drugs_contraception_and_hrt_summary_with_practical_action_plan/
Asbaghi O, Naghizadeh F, Khorvash M, Ghaedi E, Ebrahimi E, Nikooyeh B, Lari DA, Nadjarzadeh A. Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2020;161:105098. doi:10.1016/j.phrs.2020.105098. PMID: 32730903.https://pubmed.ncbi.nlm.nih.gov/32730903/
Tsang C, Taghizadeh M, Aghabagheri E, Asemi Z, Jafarnejad S. A meta-analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity. Clin Obes. 2019;9(4):e12313. doi:10.1111/cob.12313. PMID: 31115179. https://pubmed.ncbi.nlm.nih.gov/31115179/
Veronese N, Watutantrige-Fernando S, Luchini C, et al. Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials. Eur J Clin Nutr. 2016;70(12):1354-1359. doi:10.1038/ejcn.2016.154https://pubmed.ncbi.nlm.nih.gov/27530471/
Pickering G, Mazur A, Trousselard M, et al. Magnesium status and stress: the vicious circle concept revisited. Nutrients. 2020;12(12):3672. doi:10.3390/nu12123672https://pmc.ncbi.nlm.nih.gov/articles/PMC7761127/
Mascolo E, Liguori F, Merigliano C, et al. Vitamin B6 rescues insulin resistance and glucose-induced DNA damage caused by reduced activity of Drosophila PI3K. J Cell Physiol. 2022;237(9):3578-3586. doi:10.1002/jcp.30812 https://pmc.ncbi.nlm.nih.gov/articles/PMC9545242/
Pinkas J, Bojar I, Gujski M, et al. Serum lipid, vitamin D levels, and obesity in perimenopausal and postmenopausal women in non-manual employment. Med Sci Monit. 2017;23:5018-5026. doi:10.12659/msm.906895 https://pmc.ncbi.nlm.nih.gov/articles/PMC5665606/
Rasouli N, Brodsky IG, Chatterjee R, et al; D2d Research Group. Effects of vitamin D supplementation on insulin sensitivity and secretion in prediabetes. J Clin Endocrinol Metab. 2022;107(1):230-240. doi:10.1210/clinem/dgab649 https://pmc.ncbi.nlm.nih.gov/articles/PMC8684490/
Chhina GS, Chhabra A, Luthra SR, Khattar S, Singh P, Luthra S. Effect of zinc supplementation on glycemic control in newly diagnosed patients with type 2 diabetes mellitus. Cureus. 2024;16(9):e69180. doi:10.7759/cureus.69180 https://pmc.ncbi.nlm.nih.gov/articles/PMC11468580/